Jianyou Co., Ltd. announced that Emerge, a wholly-owned subsidiary of the company, recently received a BLA approval letter for insulin injections issued by the US FDA. The drug is suitable for improving blood sugar control in adults and pediatric diabetics. There are 3 approved specifications. Up to now, the company has invested about 199 million yuan in R&D expenses in this project. The approval of this product will enhance the company's international influence. If it is launched and sold later, it is expected to have a positive impact, but there is no significant impact in the short term, and there is uncertainty about subsequent sales.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.